Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-04-14 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-14 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED PRESENTATION OF PRECLINICAL DATA ON A MULTI-SPECIFIC ANTIBODY-BASED THERAPEUTIC CANDIDATE CS2006/NM21-1480 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals about the presentation of preclinical data on a therapeutic candidate at a scientific conference (AACR Annual Meeting 2022). It contains no financial statements, regulatory filings, or detailed financial performance data. It is not an earnings release, annual report, or interim report. The content focuses on scientific and clinical development updates rather than financial or governance matters. The document is an announcement of a presentation of scientific data, not a formal investor presentation or management report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2022-04-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorized and issued share capital, share options, and confirmations related to securities issued by the company CStone Pharmaceuticals. It includes data on share capital balances, share options exercised or lapsed, and confirmations by a company director regarding compliance with listing rules. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory submission detailing share capital changes and confirmations, which fits the definition of a Regulatory Filing (RNS) as it is a compliance document that does not fit into other specific categories like share issue announcements or director dealings. The document length (9009 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or a full financial report.
2022-04-06 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-01 English
Monthly Returns
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on changes in authorised/registered share capital, issued shares, share options, and confirmations related to share issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is primarily about share capital changes and share issuance details, including confirmations by a director. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is not a report like an Annual Report or Interim Report but a regulatory submission about share capital movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2022-04-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.